Gilead Sciences said total revenues for the 3 months ended June 30, 2025 increased 2% compared to the same period in the prior year to $7.1 billion, and net income attributable to Gilead was $2.0 billion (diluted earnings per share of $1.56).

10-QQuarterly reportFiled Aug 7, 2025Period of report Jun 30, 2025Summary published (UTC) Oct 10, 2026

Key points

AI summary

Gilead Sciences said total revenues for the 3 months ended June 30, 2025 increased 2% compared to the same period in the prior year to $7.1 billion, and net income attributable to Gilead was $2.0 billion (diluted earnings per share of $1.56).
The company said HIV product sales for the 3 months ended June 30, 2025 increased 7% compared to the same period in the prior year to $5.1 billion, with Biktarvy sales up 9% and Descovy sales up 35%. It cited higher demand and higher average realized price as factors.
Gilead Sciences said it recognized a partial impairment charge of $190 million on the bulevirtide IPR&D intangible asset for the 3 months ended June 30, 2025. The company cited additional competitive clinical data indicating a more competitive market in unapproved regions as the reason.
The company said it used $2.0 billion for dividend payments, $1.8 billion for debt repayment and $1.3 billion for common stock repurchases during the 6 months ended June 30, 2025. Common stock repurchases in the same period in the prior year were $500 million.

Key figures

Quarter ended June 30, 2025

Revenue: $7.1B
Operating income: $2.5B
Net income: $2.0B
EPS: $1.56

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Q2 2025 Revenue and Net Income

Gilead Sciences said total revenues for the 3 months ended June 30, 2025 increased 2% compared to the same period in the prior year to $7.1 billion, and net income attributable to Gilead was $2.0 billion (diluted earnings per share of $1.56).

Source · Based on the MD&A text of the filing

HIV Product Sales Growth

The company said HIV product sales for the 3 months ended June 30, 2025 increased 7% compared to the same period in the prior year to $5.1 billion, with Biktarvy sales up 9% and Descovy sales up 35%. It cited higher demand and higher average realized price as factors.

Source · Based on the MD&A text of the filing

Bulevirtide IPR&D Partial Impairment Charge

Gilead Sciences said it recognized a partial impairment charge of $190 million on the bulevirtide IPR&D intangible asset for the 3 months ended June 30, 2025. The company cited additional competitive clinical data indicating a more competitive market in unapproved regions as the reason.

Source · Based on the MD&A text of the filing

First-Half Financing Activities Cash Usage

The company said it used $2.0 billion for dividend payments, $1.8 billion for debt repayment and $1.3 billion for common stock repurchases during the 6 months ended June 30, 2025. Common stock repurchases in the same period in the prior year were $500 million.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.